Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN 3:40:15 PM EDT
| Market Cap (Intraday) | 81.26B |
| Current PE | 19.43 |
| Forward PE | 17.64 |
| 2yr Forward PE | 16.94 |
| 10-Day MA | $741.47 |
| 50-Day MA | $779.63 |
| 200-Day MA | $739.98 |
Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN
777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 11851
Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.